

RESEARCH ARTICLE

Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection

Olivia Estévez^{1,2}, Luis Anibarro^{2,3,4}, Elina Garet^{1,2}, Ángeles Pallares⁵, Alberto Pena⁴, Carlos Villaverde¹, Víctor del Campo⁶, África González-Fernández^{1,2*}

1 Immunology Group, CINBIO, Centro de Investigaciones Biomédicas, Universidade de Vigo, Vigo, Spain, **2** Instituto de Investigación Sanitaria Galicia Sur (IIS-GS), Vigo, Spain, **3** Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain, **4** Tuberculosis Unit, Department of Infectious Diseases and Internal Medicine, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, **5** Department of Microbiology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, **6** Epidemiology Unit, Alvaro Cunqueiro University Hospital, Vigo, Spain

* africa@uvigo.es



OPEN ACCESS

Citation: Estévez O, Anibarro L, Garet E, Pallares Á, Pena A, Villaverde C, et al. (2020) Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection. PLoS ONE 15(7): e0235859. <https://doi.org/10.1371/journal.pone.0235859>

Editor: Olivier Neyrolles, Institut de Pharmacologie et de Biologie Structurale, FRANCE

Received: March 24, 2020

Accepted: June 23, 2020

Published: July 20, 2020

Copyright: © 2020 Estévez et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the EU Horizon2020 Eliciting Mucosal Immunity in Tuberculosis (EMI-TB) project [Grant Number 643558] (<https://ec.europa.eu/programmes/horizon2020/en>) and the Xunta de Galicia “Grupo de Referencia Competitiva 2016” [Grant number ED431C 2016/041] (<https://www.edu.xunta.gal/portal/es/node/26897>). O.E. acknowledges a

Abstract

In our work, we aim to identify new candidate host biomarkers to discriminate between active TB patients (n = 28), latent infection (LTBI; n = 27) and uninfected (NoTBI; n = 42) individuals. For that, active TB patients and their contacts were recruited that donated serum and saliva samples. A multiplex assay was performed to study the concentration of different cytokines, chemokines and growth factors. Proteins with significant differences between groups were selected and logistic regression and the area under the ROC curve (AUC) was used to assess the diagnostic accuracy. The best marker combinations that discriminate active TB from NoTBI contacts were [IP-10 + IL-7] in serum and [Fractalkine + IP-10 + IL-1 α + VEGF] in saliva. Best discrimination between active TB and LTBI was achieved using [IP-10 + BCA-1] in serum (AUC = 0.83) and IP-10 in saliva ($p = 0.0007$; AUC = 0.78). The levels of TNF α ($p = 0.003$; AUC = 0.73) in serum and the combination of [Fractalkine + IL-12p40] (AUC = 0.83) in saliva, were able to differentiate between NoTBI and LTBI contacts. In conclusion, different individual and combined protein markers could help to discriminate between active TB and both uninfected and latently-infected contacts. The most promising ones include [IP-10 + IL-7], [IP-10 + BCA-1] and TNF α in serum and [Fractalkine + IP-10 + IL-1 α + VEGF], IP-10 and [Fractalkine+IL-12p40] in saliva.

Introduction

Tuberculosis (TB) remains one of the major causes of deaths worldwide, being responsible of 1.5 million deaths in the year 2018 [1]. An accurate TB diagnosis and treatment of people infected with *Mycobacterium tuberculosis* (*Mtb*) is key to prevent the death of millions of people every year. However, there are still great limitations in TB diagnostics.

Active TB diagnosis by detection of acid-fast bacilli in sputum has low sensitivity [2] and sputum culture has a long turnaround time until the final result; *ex vivo* *M. tuberculosis* gene

fellowship from the Spanish Ministry of Education [Grant number FPU 13/03026] (<http://www.educacionyfp.gob.es/servicios-al-ciudadano/catalogo/general/99/998758/ficha/998758-2019.html>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: A González-Fernández is co-promotor of the company NanoImmunoTech. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

amplification test (GeneXpert MTB/RIF) provides rapid results with high sensitivity [3]. However, this is a relatively expensive test that requires specialized infrastructure not always available in low-income areas [4]. Furthermore, none of these tests allows the detection of latent TB infection (LTBI) [5]. Currently, there is not a gold standard test for the detection of LTBI, hence the Tuberculin Skin Test (TST) or the Interferon-gamma Release Assay (IGRA) are used for this purpose. Both these tests detect immunological memory against *Mtb* antigens and neither of them can discriminate between active TB and LTBI [6].

Considering all the limitations mentioned above, it is evident the necessity of new diagnostic tools that allow the discrimination between active TB patients, latent TB infection and uninfected individuals. Direct *ex vivo* assays that could be adapted to affordable point-of-care testing are desirable. In addition, these tests should use easy-to-access biological specimens that can be obtained from all individuals. Serum and saliva samples pose several qualities that make them attractive candidates for this purpose. Serum samples are easy to collect by specialized personnel and require minimum sample processing [7]. However, one of its limitations is its invasiveness and the requirement of skilled technicians for collection. Saliva samples, on the other hand, are non-invasive, cost-effective, easy to store and easy to obtain by non-specialized personnel [8,9]. In addition, saliva represents a mucosal sample connected with the respiratory tract, the main infection route of *Mtb*. For this reason, we believe that saliva could not only be a potential tool for TB diagnosis but also a source of information of the events that take place at the mucosal level, which is of great importance in the context of pulmonary TB.

Identification of host biomarkers in serum and saliva that help to discriminate between groups is key for the development of improved diagnostic tools. Previous investigations have been done using serum, plasma [10–19] and saliva [16,20,21] samples, that identified some candidate TB biomarkers. However, there is still a lack of consensus of which are the most powerful ones to differentiate active and latent TB infection or between healthy people with or without infection. For this reason, we have performed a study in which we have analysed some of the markers most broadly studied in the context of tuberculosis, such as IFN γ or the IFN-inducible protein 10 (IP-10), but also other cytokines, chemokines and growth factors that could be contributing to the infection, and therefore present a distinct signature on the different study groups. Our research provides information of new candidate biomarkers in both serum and saliva samples, that could help on improving the diagnostic tools available to date.

Material and methods

Study participants

Participants included in the current study were recruited within the framework of the H2020 project “Eliciting Mucosal Immunity to Tuberculosis” (EMI-TB; H2020-EU.3.1: Societal Challenges; “Health, demographic change and well-being”. Reference 643558). The recruitment was conducted between September 2015 and July 2017 in at the Tuberculosis Unit in the “Complejo Hospitalario Universitario de Pontevedra” (Galicia, North-West of Spain).

The study included microbiologically-confirmed active pulmonary TB patients and their contacts, classified as uninfected (NoTBI) or with latent tuberculosis infection (LTBI). Participants were eligible for the study if they were willing to give written informed consent. People were excluded from the study if they were under 18 years old; they were pregnant; had received anti-TB treatment before; a TST was conducted in the last 3 months before the recruitment; were co-infected with HIV or were under any immunosuppressive treatment including inhaled corticosteroids. We also excluded people with diabetes, end-stage renal disease, alcoholism or any autoimmune disorder and, in general, any other immunosuppressive state as considered by the attending physician. In addition, contacts matching any of the following

conditions were also excluded: a previous TB diagnosis or TST/IGRA documented; the presence of an old-healed lesion on chest on chest radiography; a recent (<3 months) vaccination with live-attenuated strains and having had any other active infection during the previous month. The study was approved by the Galician Ethics Committee (registry number: 2014/492) and written informed consent was obtained from all participants.

Diagnostic tests

Diagnosis of TB contacts was based on the TST and, when indicated, with an IGRA test, following the Spanish consensus for TB diagnosis [22].

TST was carried out following the Mantoux method using two units of tuberculin RT-23 (PPD, Statens Serum Institute, Copenhagen, Denmark). After 48–72 hours, the induration diameter was measured. Participants with ≥ 5 mm induration area were considered TST positive. The QuantiferonTM-TB Gold In-Tube Kit (Cellestis Ltd, Carnegie, Australia) was used to measure the Interferon gamma production in antigen-stimulated blood T cells after incubation with the antigens ESAT-6, CFP10 and TB7.7, following the manufacturer's instructions. The cut-off value for a positive IGRA result was 0.35 IU/mL. A "window period" was considered in contacts with a negative TST/IGRA in their first visit. In these cases, a second test was conducted 8–10 weeks after the last possible exposure to the index case [23].

Patients with active pulmonary TB were all microbiologically confirmed by means of culture and/or Nucleic-Acid Amplification in respiratory specimens. Contacts of TB patients with positive TST/IGRA that did not show any symptoms and had no evidence of clinical and radiological disease were finally diagnosed with Latent TB infection.

Sample collection and processing

A total of 97 participants were recruited including 28 active TB patients, 42 uninfected contacts and 27 LTBI contacts. All individuals donated 10 mL of peripheral venous blood collected in SST II *Advance* (Vacutainer, BD; Plymouth, UK) serum separator tubes. The tubes were centrifuged at 1300 g for 10 min at room temperature and the serum fraction was collected, aliquoted and kept at -80°C until their use.

Saliva samples were collected in 15 mL polypropylene tubes up to a volume of 7–10 mL per participant and kept at 4°C during sample processing. The tubes were centrifuged at 300 g for 5 min and the supernatant was collected and treated with a protease inhibitor (Complete Tablet Mini, Roche; Mannheim, Germany) to avoid protein degradation. Saliva supernatants were de-contaminated by mechanical disruption on a BeadBeater device (Mini BeadBeater-16, BioSpec Products; Bartlesville, OK, USA) applying three pulses of agitation of 20 s in the presence of 0.1 mm zirconia beads (BioSpec Products; Bartlesville, OK, USA). The supernatant was recovered after centrifugation and filtered through a 0.22 μm cell strainer. Processed saliva samples were kept at -80°C and gradually thawed on ice on the day of the assay.

Multiplex immunoassay

Customized Milliplex kits (modified from the "Human Cytokine/Chemokine Panel I" (HCYTOMAG-60K), "Human Cytokine/Chemokine Panel II" (HCYP2MAG-62K) and "Human Th17" (HTH17MAG-14K) panels) were used to evaluate different proteins of the immune response. Several protein markers were studied in serum and saliva samples, including interferon (IFN)- γ and $-\alpha 2$, Tumor necrosis factor (TNF)- α and $-\beta$, IL-1 α , IL-1 β , IL-2, IL-3, IL-7, IL-12p40, IL-12p70, IL-15, IL-16, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-32, IL-1Ra, IL-4, IL-5, IL-9, IL-10, IL-13, IL-6, IL-27, IL-33, the soluble form of the CD40 ligand (sCD40L), Transforming growth factor (TGF)- α , IL-8 (CXCL-8), B cell-attracting chemokine 1 (BCA-1 or

CXCL-13), Eotaxin (CCL-11), Fibroblast Growth Factor-2 (FGF-2), FMS-related tyrosine kinase 3 Ligand (FLT-3L), Fractalkine (CX3CL1), GRO (CXCL1), interferon-inducible protein 10 (IP-10 or CXCL-10), Monocyte chemoattractant protein 1 (MCP-1 or CCL-2) and 3 (MCP-3 or CCL-7), Macrophage-derived chemokine (MDC or CCL-22), Macrophage inflammatory protein (MIP)- α and - β (or CCL-3 and CCL-4, respectively), RANTES (CCL5), Epidermal growth factor (EGF), Granulocyte-colony stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Platelet-derived growth factor (PDGF)-AA and -AB/BB and the vascular endothelial growth factor (VEGF). Serum samples were used without further dilutions after thawing and saliva samples were diluted $\frac{1}{2}$ in sterile PBS. Serum and saliva samples were evaluated on separate plates. Samples from all three groups were included on the same plate. Samples were analysed using a MagPix device (Luminex; Austin, Texas, USA) with the xPonent 4.2 software. The quality control samples for all analytes were within the expected range. A calibration curve was built based on the concentration and median fluorescence intensity of the standards that were used to calculate the concentration of each sample.

Statistical analysis

Differences between groups were evaluated using the Kruskal-Wallis test to look for general differences between the three groups (NoTBI, LTBI and TB) followed by a Dunn's Test corrected for multiple comparisons. Differences with a p -value ≤ 0.05 were considered significant. The diagnostic accuracy of the markers with significant differences between groups was assessed by the receiver operator characteristics (ROC) curve analysis. The cut-off values for each parameter were determined by the highest Youden Index [24] to maximize the sensitivity and specificity of the test. Individual markers with an area under the ROC curve (AUC) >0.7 were used to study the classification abilities of marker combinations. Binary logistic regression was applied to calculate the predicted probability of combined biomarkers for discrimination between every two groups. The predicted probability was used to construct the ROC curves and calculate the AUC. The diagnostic efficacy of the marker combinations and individual markers were compared based on the differences of the respective AUCs using the DeLong method. Statistical analysis and graph representation were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software; CA, USA), IBM SPSS version 23 for windows (SPSS Inc., Chicago, Ill., USA) and the free software R (version 3.4.3).

Results

A total of 97 patients were recruited: 28 microbiologically confirmed active TB patients, 42 uninfected contacts and 27 LTBI contacts. Table 1 summarizes the study participants, regarding age, sex and previous BCG vaccination, with a higher proportion of males, especially in the TB group.

Table 1. Characteristics of study participants.

	All	NoTBI	LTBI	TB
Number of cases	97	42	27	28
Age mean (range)	43 (19–76)	40 (19–76)	48 (19–71)	41 (21–72)
Females/Males	38/59	22/20	11/16	5/23
BCG naive/vaccinated	73/24	29/13	20/7	24/4

<https://doi.org/10.1371/journal.pone.0235859.t001>

Screening of host markers in serum samples

An initial screening was performed analysing the concentration of 46 different proteins in serum of 49 participants from the three groups. Among them, 18 markers (IL-21, IL-27, BCA-1, EGF, FGF-2, Eotaxin, TGF γ , IFN γ , GRO, MDC, IL-17A, IL-8, IP-10, MCP-1, MIP-1 γ , MIP-1 β , TNF γ and VEGF) were detected in 90–100% of the samples, two proteins were detected in 70–90% of the samples (GM-CSF and IL-7), five in 60–70% of them (IL-17, G-CSF, IL-1Ra, IL-1 β and IL-6) and the remaining were below the minimum detectable level in more than half of the samples, hence they were not considered for further analysis. Among those with detectable levels in most of the samples, we applied a Kruskal-Wallis test and only six (IL-6, IL-7, IP-10, TGF α , TNF α and BCA-1) presented significant ($p < 0.05$) differences between groups or a trend ($p < 0.1$) that suggested a different distribution. These marker candidates were then analysed in the rest of the participants and the differences between groups were further investigated.

Individual host markers in serum

The baseline concentration of the selected cytokines including IL-6, IL-7, IP-10, TGF α , TNF α and BCA-1 showed greater concentrations in serum from active TB patients than in their uninfected contacts (p values ranging between 0.05–0.0001) and, in the case of IP-10, TGF α and BCA-1, also compared to LTBI contacts ($p < 0.05$ – $p < 0.01$). No major differences were found between the two contact groups, except in TNF α , where LTBI contacts showed significantly higher concentration of this cytokine than in the NoTBI contacts ($p < 0.005$) (Fig 1, Table 2 and S1 Table). In all cases, TB patients showed higher concentrations of the studied cytokines, but LTBI contacts showed intermediate levels between uninfected contacts and TB patients.




Fig 1. Concentration of protein markers detected in serum samples. The horizontal bars represent the median and the interquartile range. Differences between study groups were calculated using a Kruskal-Wallis test followed by a Dunn's test corrected for multiple comparisons. Significant differences between groups are expressed as: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

<https://doi.org/10.1371/journal.pone.0235859.g001>

Table 2. Median levels and interquartile ranges of selected candidate host markers detected in serum samples from TB patients and contacts.

Marker	NoTBI	LTBI	TB
IL-6	0 (0–9.38)	2.74 (0–111.5)	20 (5.74–45.14)
IL-7	3.00 (0.91–4.78)	3.74 (0.19–12.73)	10.12 (5.08–26.36)
IP-10	191.6 (157.6–329.9)	282 (167.7–352.9)	483.5 (309.1–738.6)
TGF α	4.73 (3.36–8.62)	5.179 (3.36–20.18)	10.84 (7.76–19.38)
TNF α	8.74 (6.3–11.57)	16.8 (9.53–42.01)	20.32 (15.02–32.79)
BCA-1	23.26 (15.28–31.26)	23.56 (17.15–27.36)	37.4 (25.37–58.73)

NoTBI: Uninfected contacts; LTBI: Contacts with latent TB infection; TB: Active Tuberculosis patients.

<https://doi.org/10.1371/journal.pone.0235859.t002>

A ROC curve analysis was conducted to assess the diagnostic accuracies of individual host markers performing pair-wise comparisons. This analysis showed that the six markers present promising results (AUC > 0.7) differentiating active TB and NoTBI contacts, being TNF α , IL-7 and IP-10 the ones with the best discriminatory capacity (S1 Table).

For discrimination between LTBI and active TB patients, the best three protein markers were IL-7, IP-10 and BCA-1, while for NoTBI and LTBI contacts, only TNF α showed significant statistical differences (S1 Table).

Combination of host markers in serum

These individual host markers that showed significant differences between groups were further explored trying different combinations based on binary logistic regression. The best combination using the minimum number of markers was selected using a backward stepwise selection. For discrimination between active TB and NoTBI contacts, the combination with the highest AUC (0.87) and accuracy (80.1%) was IP10 + IL7 (Table 3), which presented a better performance than the individual cytokines, although no significant differences (S1 Table) were found ($Z = 1.0926$, p -value = 0.2746 and $Z = 1.5859$, p -value = 0.1128 respectively). The inclusion of either TNF α and/or TGF α (both with an AUC > 0.8), did not improve the combination IP10 + IL7.

For discrimination between LTBI and active TB patients, the three markers IP-10, BCA-1 and IL-7, that individually showed a good performance, were combined using logistic regression. The combination of IP10 + BCA-1 (the two with highest AUC) showed an AUC of 0.83 with 88% specificity and 72% sensitivity (Table 3). This combination also showed a better performance than these two markers alone. Adding up IL-7, however, did not improve the results.

Table 3. Accuracy of marker combinations in serum for the diagnosis of TB infection.

	Combination	AUC	Acc.	Sens. (%)	Spec. (%)
NoTBI vs TB	IP10 + IL7*	0.88	80.85	80	81.82
	IP10 + IL7 + TNF α	0.88	78.72	80	77.27
	IP10 + IL7 + TGF α	0.88	80.85	80	81.82
	IP10 + IL7 + TNF α + TGF α	0.88	78.72	80	77.27
LTBI vs TB	IP10 + BCA1	0.83	80.00	72	88.00
	IP10 + BCA1 + IL7	0.79	70.45	72	68.42
NoTBI vs LTBI	TNF α **	0.73	-	60	83.78

AUC: area under ROC curve. Acc: Accuracy. Sens: Sensitivity; Spec: Specificity.

*Selection made by backward elimination (Likelihood ratio).

**In the case of NoTBI versus LTBI, only TNF α showed differences.

<https://doi.org/10.1371/journal.pone.0235859.t003>

In the case of the comparison between NoTBI and LTBI contacts, we only found differences in the level of TNF α (Table 3 and S1 Table), so combinations with other cytokines were not studied.

In summary, the study in serum of just 4 cytokines: IP-10, IL-7, BCA-1 and TNF α could help to identify the three TB populations. Increasing levels of IP-10 + IL-7 would allow the discrimination between active TB and NoTBI; IP-10 + BCA-1 from active TB and LTBI contacts, and only TNF α for differentiation between NoTBI and LTBI contacts.

Screening of host markers in saliva samples

An initial screening of potential host markers in saliva samples was performed analysing 44 different proteins in 66 participants. Six out of the 44 candidates (IL-23, IL-33, IL-15, IL-17A, IL-2 and IL-3) were undetectable in all samples and six (Eotaxin, IL-4, IL-5, IL-9, sCD40L and TNF- β) were only detected in < 15% of the saliva samples. All of them were excluded for further analysis. On the other hand, 18 protein markers (EGF, Fractalkine, GMCSF, GRO, GCSF, IL-1 α , IL-1 β , IL-1Ra, IL-7, IL-8, IFN- α 2, MCP-1, MDC, PDGF-AA, PDGF-AB/BB, TGF- α , TNF- α and VEGF) were above the minimum detectable level in >90% samples; Nine (IL-16, FGF-2, FLT-3L, IL-13, IL-6, IL-9, IFN- γ , IP-10 and MIP- α) were detected in 70–90% of the samples and six (IL-10, IL-12p40, IL-12p70, MCP-3, MIP- β and RANTES) had detectable levels in 50–70% of the samples. From them, thirteen markers (IL-16, EGF, Fractalkine, GRO, IL-12p40, IL-1 α , IL-6, IFN- α 2, IP-10, MCP-1, MIP-alpha, TGF- α , VEGF) showed significant differences between groups ($p < 0.05$) when applying a Kruskal-Wallis test. These were selected for further analysis using the remaining saliva samples.

Individual host markers in saliva

The thirteen candidate markers selected in saliva samples (see [material and methods](#)) were studied in a total of 89 participants from the three groups (34 NoTBI, 27 LTBI and 28 TB). This analysis showed that, overall, these protein markers were present in higher concentrations in saliva of active TB patients, with the exception of IL-12p40 and IL-1 α , that were more abundant in saliva of NoTBI contacts (Table 4, Fig 2). In most cases LTBI contacts showed an intermediate level between NoTBI and TB patients.

Table 4. Median levels and interquartile ranges of selected candidate host markers detected in saliva samples from the TB patients and uninfected and with latent infection contacts.

Marker	Median (interquartile range)		
	NoTBI	LTBI	TB
TGF α	4.92 (3.20–6.74)	5.56 (3.59–9.18)	7.822 (4.53–12.89)
Fractalkine	179.4 (123.7–206.4)	258.8 (192.3–381.4)	346.1 (244.4–474.6)
IFN α 2	19.7 (11.15–39.24)	24.55 (10.16–31.24)	32.91 (18.1–63.53)
GRO	35.77 (24.87–92.34)	65.38 (25.69–300.6)	158.1 (51.72–661.4)
IL-12p40	4.807 (1.76–18.88)	0 (0–3.756)	2.326 (0–5.2)
IL-1 α	1331 (726.8–2430)	965 (436.2–1559)	670.5 (415.6–840.5)
IL-6	2.1 (0.11–5.27)	2.0 (0.32–5.97)	6.1 (1.68–11.56)
IP-10	21.1 (0–57.04)	13.05 (0–56.35)	72.49 (27.6–415.3)
MCP-1	140.5 (43.23–285)	141.9 (75.96–647.2)	349.8 (152.8–589.3)
MIP-1 α	5.719 (1.6–11.1)	7.123 (1.851–13.77)	11.32 (5.766–25.55)
VEGF	48.57 (27.79–104.9)	60.28 (31.76–126.4)	124.7 (56.14–260.3)

NoTBI: Uninfected contacts; LTBI: contacts with latent infection; TB: Active Tuberculosis patients; AUC: Area under the ROC curve; Cut off: marker concentration cut off with the best Youden index; CI: Confidence interval.

<https://doi.org/10.1371/journal.pone.0235859.t004>




Fig 2. Concentration of protein markers detected in saliva samples. The horizontal bars represent the median and the interquartile range. Differences between study groups were calculated using a Kruskal-Wallis test followed by a Dunn's test corrected for multiple comparisons. Significant differences between groups are expressed as: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$ and ns: no significant differences.

<https://doi.org/10.1371/journal.pone.0235859.g002>

The greatest differences were found between active TB and NoTBI contacts, with most of the markers (TGF- α , Fractalkine, IFN- α 2, GRO, IL-6, IP-10, MCP-1, MIP-1a and VEGF) showing significant differences ($p < 0.05$ – $p < 0.0001$) between these two groups, except for IL-12p40, which only showed significant differences between NoTBI and LTBI ($p < 0.05$), and IL-16 and EGF, that did not present significant differences between groups. In addition, IFN- α 2 ($p < 0.05$), IP-10 ($p < 0.001$) and VEGF ($p < 0.05$) were significantly higher in active TB compared to LTBI contacts and Fractalkine was also significantly higher ($p < 0.05$) in LTBI than in NoTBI contacts (Fig 2).

The discriminatory capacity of each marker with significant differences between groups was evaluated performing a ROC analysis (S2 Table). The most promising host marker for discrimination between active TB and NoTBI in saliva was Fractalkine, with an AUC of 0.87, 78.57% sensitivity and 81.25% specificity at the selected cut-off (S2 Table). Other markers with good performance (AUC > 0.7) were GRO, IL-1 α , IP-10, MCP-1, MIP-1 α and VEGF (S2 Table).

As for the markers that were able to discriminate between LTBI and active TB, we found that IFN- α 2 and IP-10 were the most promising ones (S2 Table). The sensitivity and specificity values were between 58.62% and 80.77%, showing a slightly worse performance than markers from serum samples. Finally, Fractalkine (AUC = 0.73; 69.2% Sensitivity and 75% Specificity) and IL-12p40 (AUC = 0.73; 74.1% Sensitivity and 72% Specificity) showed the best performance discriminating between NoTBI and LTBI contacts (S2 Table).

Combination of host markers in saliva

Combinations of individual candidate markers in saliva were studied including those with an individual AUC > 0.7. Candidate markers were fitted into logistic regression models to evaluate their classification performance. For discrimination between active TB and NoTBI, the combination of Fractalkine + IP10 + IL1 α + VEGF was selected using a backward elimination approach, which showed an AUC of 0.88 (83.61% accurately classified samples, 91.2% specificity and 74% sensitivity) (Table 5). The combination presented a significantly better performance than individual IP-10 ($Z = 1.9167$, p -value = 0.05), IL1 α ($Z = 2.1925$, p -value = 0.02834) or VEGF ($Z = 6.6681$, p -value = 2.591e-11), and despite differences with Fractalkine were not significant ($Z = 1.1516$, p -value = 0.2495), it did show a higher AUC than this chemokine alone.

Two different combinations were assessed to discriminate between LTBI and active TB. First, we tried combining the candidates with the highest individual performance (IP-10 and IFN α 2), which showed an AUC of 0.67 (59.6% accuracy, 68% specificity and 51.9% sensitivity). A second combination was assessed using a backward elimination approach. The selected combination (GRO + IL6 + IP-10 + MIP1 α) showed a better performance, with an AUC of 0.77. The differences between the ROC curves of these two combinations, however, were not

Table 5. Accuracy of marker combinations in saliva for the diagnosis of TB infection.

	Combination	AUC	Acc.	Sens. (%)	Spec. (%)
NoTBI vs TB	Fractalkine + IP10 + IL1 α + VEGF*	0.88	83.61	74.07	91.18
LTBI vs TB	IP10 + IFN α 2	0.68	59.62	51.85	68.00
	GRO + IL-6 + IP10 + MIP1 α *	0.77	65.22	64.00	66.67
NoTBI vs LTBI	Fractalkine + IL-12p40	0.83	82.76	76.92	87.50

*Selections made by backward elimination (likelihood ratio). AUC: area under the ROC curve. Acc: Accuracy. Sens: Sensitivity; Spec: Specificity.

<https://doi.org/10.1371/journal.pone.0235859.t005>

significantly different, nor did they improve the individual performance of IP-10 and IFN α 2 (Table 5).

Finally, a marker combination for discrimination between NoTBI and LTBI contacts was assessed combining Fractalkine and IL-12p40 (Table 5). This combination showed a better performance than the two markers alone, with an AUC of 0.83, and a ROC curve significantly better than that of Fractalkine ($Z = 2.7566$, p -value = 0.005841) and improved trend compared to IL-12p40 alone ($Z = 1.6817$, p -value = 0.09262).

In summary, different markers in saliva showed promising results: Fractalkine + IP10 + IL1 α + VEGF discriminate between active TB and NoTBI contacts; Fractalkine + IL-12p40 differentiate LTBI from NoTBI contacts. On the other hand, discrimination between LTBI and TB using a marker combination did not improve the performance of individual IP-10 or IFN α 2.

Discussion

New tools for rapid and accurate TB diagnosis are needed in order to identify all *Mtb* infected people and differentiate active and latent TB infection. Saliva and serum samples, which are relatively easy to obtain, are ideal specimens for the identification of candidate biomarkers that could be used for the development of the required diagnostic tools. In our work, we analysed up to 50 different markers in serum and saliva and identified six markers in serum (IL-6, IL-7, IP-10, TGF α , TNF α and BCA-1) and nine in saliva (Fractalkine, GRO, IL-1 α , IP-10, MCP-1, MIP-1 α , VEGF, IFN α 2 and IL-12p40) that showed promising potential for that purpose.

As we showed here, the host markers that best define either the serum or saliva signature are different for each specimen, even though the initial screening included almost the same array of markers. These results evidence the different composition of serum and saliva. Although saliva content can include components derived from blood, these analytes usually present different concentrations in both fluids [25]. This explains why, in our work, some proteins can be a promising biomarker in one specimen (such as Fractalkine in saliva) and yet be below the minimum detectable concentration in a high proportion of serum samples. In fact, previous investigations comparing serum and saliva samples in the context of TB infection [14,16] reported different concentrations of the same host proteins in both specimens. This supports the approach followed in the present study, where an independent analysis and marker selection was made for serum and saliva.

Among the host candidates identified in serum samples, IP-10 was the one with the best performance differentiating active TB patients from both uninfected and LTBI contacts, as proved by its area under the ROC curve. These results support the research done by other groups [26–30], confirming the suitability of this marker for TB diagnosis. As opposed to TB diagnostic tests based on the IFN γ concentrations (IGRA), which require an incubation period with *Mtb* antigens, IP-10 has been shown in ours and other studies [26,31–33] to be increased in serum, plasma and urine of TB patients without requiring further stimulation. Of note, in our work IFN γ was rejected for further analysis in the preliminary screening, as it did not show significant differences between groups. Hence indicating a poor utility of IFN γ as TB biomarker without prior *in vitro* stimulation.

Moreover, we showed that accuracy of IP-10 as an individual biomarker can be improved when combined with IL-7 for discrimination between active TB and NoTBI contacts, or combined with BCA-1 to differentiate active TB and LTBI. Although previous studies have analysed an array of biomarkers in serum or plasma samples for TB diagnosis [10–16], none of them have proposed IL-7 or BCA-1 as potential biomarkers before. Our results suggest that they could not only be used in combination with IP-10, but they showed a good performance

differentiating active TB from both NoTBI and LTBI contacts when used individually, based on their respective AUCs.

Biologically speaking, a higher concentration of IP-10 and BCA-1 in serum samples from active TB patients could be related with immune cell migration to the site of infection. IP-10 and BCA-1 are two chemokines with chemoattractant properties over cells expressing the receptor CXCR3 [34,35], which include Th1 cells, one of the major participants in cellular immunity against *M. tuberculosis* infection [36]. IL-7, on the other hand, has been associated with enhanced recall responses of *Mtb*-specific CD4⁺ T cells *in vitro* [37], therefore suggesting a protective role. However, other studies described an impaired T-cell sensitivity to IL-7, with decreased soluble and membrane-bound IL-7 receptor and increased IL-7 plasma concentrations in TB [38]. This indicates that higher levels of IL-7 do not necessarily imply protection in active TB patients, although it could be used as a potential biomarker of TB.

Other individual serum markers identified in our work included IL-6 and TGF α , both showing a good performance differentiating active TB from uninfected contacts. Our results agree with previous studies [12–14,16] that had reported diagnostic potential of IL-6, which indicates the robustness of this biomarker in different geographical settings. However, we have not found in the literature previous references of TGF α as a potential TB biomarker, which suggests that further research is required to investigate this new candidate.

It is also worth mention that one of the markers included in our study, TNF α , showed a good performance differentiating uninfected and LTBI contacts. This finding has a particular interest, as differentiation between healthy individuals with or without latent infection is normally only possible after antigen-specific activation. TNF α is a critical cytokine for granuloma formation and maintenance, with an important role in controlling *Mtb* infection [39]. This would explain why patients with latent infection have higher levels of TNF α than uninfected contacts.

Regarding the marker signature found in saliva, Fractalkine was the individual marker with the best performance differentiating active TB and NoTBI contacts. A higher concentration of Fractalkine in saliva from active TB patients was also found by Phalane *et al.* [16], supporting our results. In addition, our work also provides information of a higher concentration of this chemokine in LTBI contacts and a good performance differentiating LTBI from uninfected contacts. These findings indicate the interest of this chemokine and its potential role as a saliva TB biomarker.

Our study suggested that discrimination between active TB and NoTBI contacts could be done using Fractalkine alone or in combination with IP-10, IL-1 α and VEGF, which provided a higher sensitivity and specificity than any of the markers individually. Three of these candidates, IP-10, Fractalkine and VEGF were found in higher concentrations in saliva from active TB patients, while IL-1 α was more abundant in NoTBI patients. Higher concentration of IP-10 could be related with an active cell migration, as discussed above, which could be also reflected in saliva. In the case of Fractalkine and VEGF, we believe there is a connection between their higher concentration in saliva from active TB patients and increased levels of these chemokines in lung cells [40], bronchoalveolar lavage [41] and pleural effusions [42] previously reported in patients with pulmonary tuberculosis. These observations suggest that biomarkers found in saliva could be reflecting the events that take place in the lungs.

Both Fractalkine and VEGF are expressed by endothelial cells to mediate lymphocyte chemoattraction and adhesion in mucosal tissues [43] and promote formation of new blood vessels [44], respectively. Although the role of these proteins during TB infection has not been established, previous studies in animal models suggested that Fractalkine could mediate cellular infection and spread of *Mtb* bacilli [45] and VEGF has been suggested as a mechanism for

Mtb spreading [46]. All this suggests that endothelial cells have an influence on the markers detected in saliva, and could be indirectly related with *Mtb* spreading in active TB patients.

Besides those included in the four-marker panel, other individual candidate markers were detected in saliva that could discriminate active TB and NoTBI contacts. These included GRO, MCP-1 and MIP-1 α , three chemokines known to be involved in the recruitment of neutrophils [47] and in the neutrophil-mediated immune response against *Mtb* infection [48]. In addition, there exist evidences suggesting that GRO could be related to TB pathogenesis in the lungs [49]; MCP-1 is more produced by monocytes from active TB patients and healthy controls [50] and MIP-1 α was seen to contribute to the innate immune response to *M. tuberculosis* infection [51]. All these evidences suggest that markers detected in saliva samples might reflect the innate-mediated mechanisms triggered against *Mtb* infection.

Our study also indicated that discrimination of LTBI contacts and active TB patients using saliva could be possible using IP-10 or IFN α 2. To our knowledge, this is the first time IFN α 2 is proposed as a potential biomarker to discriminate active and latent TB infection in saliva samples. On the other hand, for discrimination between uninfected and LTBI contacts, IL-12p40 was the most promising candidate.

IL-12p40 and the already mentioned IL-1 α were the only cytokines identified in our study that presented higher concentrations in NoTBI contacts. Higher concentrations of these markers in uninfected contacts could correlate with studies suggesting their role in protection against *Mtb* infection during the first stages of the disease [52–55].

One limitation of our study is its relatively small sample size. However, this was planned as a discovery study to provide new candidate markers that could be further evaluated in future works. Therefore, we prioritized the quality of the study cohort by selecting only those patients and contacts without any condition that could interfere with the immune response signature. Hence allowing for an effective analysis of the immune responses without interferences. With the current analysis, we provided confirmation of previous findings, such as the great potential of IP-10 not only in blood-derived samples, but also in saliva, and we also provided data supporting the potential of IL-6 and Fractalkine as serum and saliva biomarkers, respectively. More importantly, we propose new candidates to be used in serum (TGF α , IL-7) or saliva (MIP1 α , VEGF, GRO, MCP-1) to differentiate different TB study groups and biomarker combinations with promising discriminatory capacity that could set the basis for point-of-care tests based on affordable platforms.

Marker combinations proposed for its use in serum samples included IP-10+IL-7 or/and IP-10+BCA-1 for discrimination between active TB patients and uninfected and latently infected contacts, respectively. As for the marker combinations proposed for its use in saliva, Fractalkine + IP-10 + IL-1 α + VEGF can discriminate active TB from NoTBI contacts. Finally, the study of Fractalkine + IL-12p40 could differentiate between uninfected and LTBI contacts, being of special interest taking into account that until now, no other methods than the Tuberculin skin test or the Interferon gamma release assays (IGRA) can discriminate between these two populations.

Supporting information

S1 Table. Median levels and interquartile ranges of selected candidate host markers detected in serum samples from TB patients, uninfected and with latent infection contacts and their p values and diagnostic performance.
(DOCX)

S2 Table. Median levels and interquartile ranges of selected candidate host markers detected in saliva samples from the TB patients, uninfected and with latent infection

contacts, and their p values and diagnostic performance.
(DOCX)

Acknowledgments

We would like to thank the specialized personnel of “Complejo Hospitalario Universitario de Pontevedra” (SERGAS) for collecting and processing samples and all the TB patients and their household contacts for participating in the present study and their altruistic donation of blood and saliva samples. We also thank Alberto Lema for his advice on statistics analysis and all the Immunology group members for their help and support.

Author Contributions

Conceptualization: Luis Anibarro, África González-Fernández.

Data curation: Olivia Estévez.

Formal analysis: Olivia Estévez, Elina Garet, Carlos Villaverde, Víctor del Campo.

Funding acquisition: África González-Fernández.

Investigation: Olivia Estévez, Luis Anibarro, Elina Garet, Ángeles Pallares, Alberto Pena.

Methodology: Olivia Estévez, Elina Garet, Ángeles Pallares, Alberto Pena.

Resources: Luis Anibarro, África González-Fernández.

Supervision: África González-Fernández.

Writing – original draft: Olivia Estévez.

Writing – review & editing: Luis Anibarro, Víctor del Campo, África González-Fernández.

References

1. World Health Organization. Global Tuberculosis Report 2019. 2019. Recuperado: https://www.who.int/tb/publications/global_report/en/
2. Davies PDO, Pai M. The diagnosis and misdiagnosis of tuberculosis. *Int J Tuberc Lung Dis*. 2008; 12: 1226–1234. State of the art series. Tuberculosis. Edited by ID Rusen. PMID: 18926032
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. *N Engl J Med*. 2010; 363: 1005–1015. <https://doi.org/10.1056/NEJMoa0907847> PMID: 20825313
4. Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how? *Int J Tuberc Lung Dis*. 2011; 15: 1567–1571. <https://doi.org/10.5588/ijtld.11.0392> PMID: 22005110
5. Yong YK, Tan HY, Saeidi A, Wong WF, Vignesh R, Velu V, et al. Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. *Frontiers in Microbiology*. *Frontiers Media S.A.*; 2019; 10: 2789. <https://doi.org/10.3389/fmicb.2019.02789> PMID: 31921004
6. Pai M, Sotgiu G. Diagnostics for latent TB infection: incremental, not transformative progress. *Eur Respir J*. 2016; 47: 704–706. <https://doi.org/10.1183/13993003.01910-2015> PMID: 26929311
7. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group. *J Proteome Res*. 2009; 8: 113–117. <https://doi.org/10.1021/pr800545q> PMID: 19072545
8. Nunes LAS, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: A systematic review. *Biochemia Medica*. *Biochemia Medica, Editorial Office*; 2015; 25(2): 177–192. <https://doi.org/10.11613/BM.2015.018> PMID: 26110030
9. Malathi N, Mythili S, Vasanthi HR. Salivary Diagnostics: A Brief Review. *ISRN Dent*. 2014; 2014: 158786. <https://doi.org/10.1155/2014/158786> PMID: 24616813

10. Chen T, Li Z, Yu L, Li H, Lin J, Guo H, et al. Profiling the human immune response to *Mycobacterium tuberculosis* by human cytokine array. *Tuberculosis*. 2016; 97: 108–117. <https://doi.org/10.1016/j.tube.2015.12.007> PMID: 26980502
11. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. *J Infect*. 2013; 66: 357–365. <https://doi.org/10.1016/j.jinf.2012.11.005> PMID: 23178506
12. Ravindran R, Krishnan V V, Khanum A, Luciw PA, Khan IH. Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients. *Clin Vaccine Immunol*. 2013; 20: 1283–1290. <https://doi.org/10.1128/CVI.00213-13> PMID: 23761664
13. Farr K, Ravindran R, Strnad L, Chang E, Chaisson LH, Yoon C, et al. Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV. Ivanyi J, editor. *PLoS One*. 2018; 13: e0206119. <https://doi.org/10.1371/journal.pone.0206119> PMID: 30352099
14. Namuganga AR, Chegou NN, Mubiri P, Walz G, Mayanja-Kizza H. Suitability of saliva for Tuberculosis diagnosis: comparing with serum. *BMC Infect Dis*. 2017; 17(1): 600. <https://doi.org/10.1186/s12879-017-2687-z> PMID: 28859607
15. Hur YG, Kang YA, Jang SH, Hong JY, Kim A, Lee SA, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. *J Infect*. 2015; 70: 346–355. <https://doi.org/10.1016/j.jinf.2014.10.019> PMID: 25452040
16. Phalane KG, Kriel M, Loxton AG, Menezes A, Stanley K, van der Spuy GD, <https://doi.org/10.1155/2013/981984> Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. *Mediators Inflamm*. 2013; 2013: 981984. PMID: 24327799
17. Mateos J, Estévez O, González-Fernández Á, Anibarro L, Pallarés Á, Reljic R, et al. Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during *Mycobacterium tuberculosis* infection. *Sci Rep*. 2020; 10: 1–12. <https://doi.org/10.1038/s41598-020-60753-5>
18. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. *Lancet*. 2006; 368: 1012–1021. [https://doi.org/10.1016/S0140-6736\(06\)69342-2](https://doi.org/10.1016/S0140-6736(06)69342-2) PMID: 16980117
19. Wang S, Li Y, Shen Y, Wu J, Gao Y, Zhang S, et al. Screening and identification of a six-cytokine bio-signature for detecting TB infection and discriminating active from latent TB. *J Transl Med*. 2018; 16: 1–13. <https://doi.org/10.1186/s12967-017-1374-6>
20. Jacobs R, Tshela E, Malherbe S, Kriel M, Loxton AG, Stanley K, et al. Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment. *Cytokine*. 2016; 81: 50–56. <https://doi.org/10.1016/j.cyto.2016.02.004> PMID: 26878648
21. Jacobs R, Maasdorp E, Malherbe S, Loxton AG, Stanley K, van der Spuy G, et al. Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response. *PLoS One*. 2016; 11: e0160546. <https://doi.org/10.1371/journal.pone.0160546> PMID: 27487181
22. González-Martín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R, et al. Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. *Enferm Infecc Microbiol Clin*. 2010; 28: 297.e1–297.e20. <https://doi.org/10.1016/j.eimc.2010.02.006> PMID: 20435388
23. Anibarro L, Trigo M, Villaverde C, Pena A, Cortizo S, Sande D, et al. Interferon- γ release assays in tuberculosis contacts: is there a window period? *Eur Respir J*. 2011; 37: 215–217. <https://doi.org/10.1183/09031936.00030610> PMID: 21205718
24. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its Associated Cutoff Point. *Biometrical J*. 2005; 47: 458–472. <https://doi.org/10.1002/bimj.200410135> PMID: 16161804
25. Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DTW. Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities. *Clin Microbiol Rev*. 2013; 26: 781–791. <https://doi.org/10.1128/CMR.00021-13> PMID: 24092855
26. Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. *J Infect*. 2015; 70: 381–391. <https://doi.org/10.1016/j.jinf.2014.12.019> PMID: 25597826
27. Zambuzi FA, Cardoso-Silva PM, Espindola MS, Soares LS, Galvão-Lima LJ, Brauer VS, et al. Identification of promising plasma immune biomarkers to differentiate active pulmonary tuberculosis. *Cytokine*. 2016; 88: 99–107. <https://doi.org/10.1016/j.cyto.2016.08.030> PMID: 27591510
28. Xiong W, Dong H, Wang J, Zou X, Wen Q, Luo W, et al. Analysis of Plasma Cytokine and Chemokine Profiles in Patients with and without Tuberculosis by Liquid Array-Based Multiplexed Immunoassays. Wilkinson KA, editor. *PLoS One*. 2016; 11: e0148885. <https://doi.org/10.1371/journal.pone.0148885> PMID: 26881918

29. Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. *Expert Rev Mol Diagn.* 2012; 12: 175–187. <https://doi.org/10.1586/erm.11.97> PMID: 22369377
30. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with *M. tuberculosis*. *Tuberculosis.* 2011; 91: 260–267. <https://doi.org/10.1016/j.tube.2011.01.001> PMID: 21459676
31. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, et al. IFN- γ -inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in *Mycobacterium tuberculosis* infection. *Microbes Infect.* 2005; 7: 1–8. <https://doi.org/10.1016/j.micinf.2004.09.004> PMID: 15716076
32. Kim SY, Kim J, Kim DR, Kang YA, Bong S, Lee J, et al. Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis. *BMC Infect Dis.* 2018; 18: 240. <https://doi.org/10.1186/s12879-018-3144-3> PMID: 29843631
33. Zhao Y, Yang X, Zhang X, Yu Q, Zhao P, Wang J, et al. IP-10 and RANTES as biomarkers for pulmonary tuberculosis diagnosis and monitoring. *Tuberculosis.* 2018; 111: 45–53. <https://doi.org/10.1016/j.tube.2018.05.004> PMID: 30029914
34. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev.* 2011; 22: 121–30. <https://doi.org/10.1016/j.cytogfr.2011.06.001> PMID: 21802343
35. Jenh C-H, Cox MA, Hipkin W, Lu T, Pugliese-Sivo C, Gonsiorek W, et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. *Cytokine.* 2001; 15: 113–121. <https://doi.org/10.1006/cyto.2001.0923> PMID: 11554781
36. Flynn JL, Chan J. Immunology of Tuberculosis. *Annu Rev Immunol.* 2001; 19: 93–129. <https://doi.org/10.1146/annurev.immunol.19.1.93> PMID: 11244032
37. Terrazzini N, Mantegani P, Kern F, Fortis C, Mondino A, Caserta S. Interleukin-7 unveils pathogen-specific T Cells by enhancing antigen-recall responses. *J Infect Dis.* 2018; 217: 1997–2007. <https://doi.org/10.1093/infdis/jiy096> PMID: 29506153
38. Lundtoft C, Afum-Adjei Awuah A, Rimpler J, Harling K, Nausch N, Kohns M, et al. Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis. *PLoS Pathog.* 2017; 13: e1006425. <https://doi.org/10.1371/journal.ppat.1006425> PMID: 28582466
39. Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor Necrosis Factor and Tuberculosis. *J Investig Dermatol Symp Proc.* 2007; 12: 22–25. <https://doi.org/10.1038/SJ.JIDSYMP.5650027> PMID: 17502865
40. Stanton L-A, Fenhalls G, Lucas A, Gough P, Greaves DR, Mahoney JA, et al. Immunophenotyping of macrophages in human pulmonary tuberculosis and sarcoidosis. *Int J Exp Pathol.* 2004; 84: 289–304. <https://doi.org/10.1111/j.0959-9673.2003.00365.x> PMID: 14748748
41. Lesho E, Forestiero FJ, Hirata MH, Hirata RD, Cecon L, Melo FF, et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. *Tuberculosis (Edinb).* 2011; 91: 390–399. <https://doi.org/10.1016/j.tube.2011.07.002> PMID: 21835698
42. Jin H., Lee K., Jin S., Lee Y. Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion. *Respir Med.* 2004; 98: 115–122. <https://doi.org/10.1016/j.rmed.2003.09.002> PMID: 14971873
43. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. *J Immunol.* 2000; 164: 3368–3376. <https://doi.org/10.4049/jimmunol.164.6.3368> PMID: 10706732
44. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development.* 1992; 114: 521–532. PMID: 1592003
45. Hingley-Wilson SM, Connell D, Pollock K, Hsu T, Tchilian E, Sykes A, et al. ESX1-dependent fractalkine mediates chemotaxis and *Mycobacterium tuberculosis* infection in humans. *Tuberculosis (Edinb).* 2014; 94: 262–270. <https://doi.org/10.1016/j.tube.2014.01.004> PMID: 24631198
46. Polena H, Boudou F, Tilleul S, Dubois-Colas N, Lecoine C, Rakotosamimanana N, et al. *Mycobacterium tuberculosis* exploits the formation of new blood vessels for its dissemination. *Sci Rep.* 2016; 6: 33162. <https://doi.org/10.1038/srep33162> PMID: 27616470
47. Sawant K V., Poluri KM, Dutta AK, Sepuru KM, Troshkina A, Garofalo RP, et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. *Sci Rep.* 2016; 6: 33123. <https://doi.org/10.1038/srep33123> PMID: 27625115
48. Hilda JN, Narasimhan M, Das SD. Neutrophils from pulmonary tuberculosis patients show augmented levels of chemokines MIP-1 α , IL-8 and MCP-1 which further increase upon in vitro infection with

- mycobacterial strains. *Hum Immunol.* 2014; 75: 914–922. <https://doi.org/10.1016/j.humimm.2014.06.020> PMID: 24994463
49. Niazi MKK, Dhulekar N, Schmidt D, Major S, Cooper R, Abeijon C, et al. Lung necrosis and neutrophils reflect common pathways of susceptibility to *Mycobacterium tuberculosis* in genetically diverse, immune-competent mice. *Dis Model Mech.* 2015; 8: 1141–1153. <https://doi.org/10.1242/dmm.020867> PMID: 26204894
 50. Lin Y, Gong J, Zhang M, Xue W, Barnes PF. Production of monocyte chemoattractant protein 1 in tuberculosis patients. *Infect Immun.* 1998; 66: 2319–2322. PMID: 9573123
 51. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by *Mycobacterium tuberculosis* and inhibit its growth. *Infect Immun.* 2002; 70: 1684–1693. <https://doi.org/10.1128/iai.70.4.1684-1693.2002> PMID: 11895930
 52. Bourigault M-L, Segueni N, Rose S, Court N, Vacher R, Vasseur V, et al. Relative contribution of IL-1 α , IL-1 β and TNF to the host response to *Mycobacterium tuberculosis* and attenuated *M. bovis* BCG. *Immunity, Inflamm Dis.* 2013; 1: 47–62. <https://doi.org/10.1002/iid3.9> PMID: 25400917
 53. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. *Lab Invest.* 2000; 80(5): 759–767. <https://doi.org/10.1038/labinvest.3780079> PMID: 10830786
 54. Hölscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. *J Immunol.* 2001; 167(12): 6957–6966. <https://doi.org/10.4049/jimmunol.167.12.6957> PMID: 11739515
 55. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after *Mycobacterium tuberculosis* infection. *J Exp Med.* 2006; 203: 1805–1815. <https://doi.org/10.1084/jem.20052545> PMID: 16818672